Supplemental material
Open access
2,264
Views
0
CrossRef citations to date
0
Altmetric
Articles
Abrocitinib monotherapy in Investigator’s Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life
Andrew Blauvelta Department of Dermatology, Oregon Medical Research Center, Portland, OR, USAView further author information
, Mark Boguniewiczb Division of Allergy and Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, CO, USAView further author information
, Patrick M. Brunnerc Department of Dermatology, Medical University of Vienna, Vienna, Austria, and Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USAView further author information
, Paula C. Lunad Dermatology Department, Hospital Alemán, Buenos Aires, ArgentinaView further author information
, Pinaki Biswase Pfizer Inc, New York, NY, USAView further author information
, Marco DiBonaventurae Pfizer Inc, New York, NY, USAView further author information
, Saleem A. Farooquif Pfizer R&D UK Ltd, Sandwich, UKView further author information
, Ricardo Rojog Pfizer Inc, Groton, CT, USAView further author information
& Michael C. Camerone Pfizer Inc, New York, NY, USACorrespondence[email protected]
View further author information
show allView further author information
Pages 2605-2613
|
Received 04 Mar 2022, Accepted 22 Mar 2022, Published online: 06 Jul 2022
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.